Sentences with phrase «transcatheter aortic heart»

The company develops and markets a broad range of medical devices, such as advanced surgical technology, insulin pumps, transcatheter aortic heart valves, and much more.

Not exact matches

Transcatheter aortic valve replacement (TAVR) is used to replace a critically narrowed aortic valve, the valve between the heart and the main artery in the body.

UCLA scientists have found that conscious sedation — a type of anesthesia in which patients remain awake but are sleepy and pain - free — is a safe and viable option to general anesthesia for people undergoing a minimally invasive heart procedure called transcatheter aortic valve replacement.

In recent years, the use of transcatheter aortic valve replacement, or TAVR, has made the repair safer: Physicians place a new valve in the heart via a catheter inserted through the patient's leg, which results in less injury and an easier recovery than open heart surgery.

The more frequently a hospital performs a minimally invasive technique called transcatheter aortic valve replacement, or TAVR, to replace a damaged aortic heart valve, the better patients fare, on average, immediately after the procedure, researchers reported at the American College of Cardiology's 65th Annual Scientific Session.

The FDA approved the CoreValve System to treat patients with severe aortic stenosis who are at high risk for surgery based on groundbreaking research showing the transcatheter heart valve had superior survival rates at one year when compared to open - heart surgery, the current gold standard for aortic valve replacement.

With this latest approval, the Orlando Health Heart Institute now also offers the CoreValve System to patients who are considered at high risk for a surgical heart procedure, serving a broader range of U.S. patients than any other transcatheter aortic vHeart Institute now also offers the CoreValve System to patients who are considered at high risk for a surgical heart procedure, serving a broader range of U.S. patients than any other transcatheter aortic vheart procedure, serving a broader range of U.S. patients than any other transcatheter aortic valve.

Boston Scientific Corporation (NYSE: BSX) announced a definitive agreement to acquire Symetis SA, a privately - held Swiss structural heart company focused on minimally - invasive transcatheter aortic...

Boston Scientific Corporation (NYSE: BSX) announced a definitive agreement to acquire Symetis SA, a privately - held Swiss structural heart company focused on minimally - invasive transcatheter aortic valve implantation (TAVI) devices, for $ 435 million in up - front cash.